Before taking Vonjo(Pacritinib)

VONJO carries several important warnings that necessitate careful patient monitoring and management before and during therapy.

Before taking Vonjo(Pacritinib)

Key precautions include the risk of serious and fatal hemorrhage, particularly in patients with low platelet counts, requiring treatment interruption before surgical procedures. Significant diarrhea must be proactively managed with anti-diarrheal agents and fluid replacement. Regular monitoring of platelet counts and electrocardiograms is essential due to risks of thrombocytopenia and QT prolongation. Concomitant use of strong CYP3A4 inhibitors or inducers is contraindicated. Caution is advised regarding potential increased risks of major cardiovascular events, thrombosis, secondary malignancies, and serious infections.